Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229–263. https://doi.org/10.3322/caac.21834

Article  PubMed  Google Scholar 

Tilki D, Van Den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 Update: treatment of relapsing and metastatic prostate cancer. Eur Urol 86:164–182. https://doi.org/10.1016/j.eururo.2024.04.010

Article  CAS  PubMed  Google Scholar 

Cornford P, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71:630–642. https://doi.org/10.1016/j.eururo.2016.08.002

Article  PubMed  Google Scholar 

Freedland SJ, De Almeida Luz M, De Giorgi U et al (2023) Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med 389:1453–1465

Article  CAS  PubMed  Google Scholar 

Aggarwal R, Heller G, Hillman DW et al (2024) Presto: A Phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19). J Clin Oncol 42:1114–1123

Article  CAS  PubMed  Google Scholar 

Kumar RJ, Barqawi A, Crawford ED (2005) Adverse events associated with hormonal therapy for prostate cancer. Rev Urol 7(Suppl 5):S37–S43

PubMed  PubMed Central  Google Scholar 

Shipley WU, Seiferheld W, Lukka HR et al (2017) Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376:417–428

Article  PubMed  PubMed Central  Google Scholar 

Trock BJ, Han M, Freedland SJ et al (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299:2760–2769

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stephenson AJ, Scardino PT, Kattan MW et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035–2041

Article  PubMed  Google Scholar 

Jambor I, Kuisma A, Ramadan S et al (2016) Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol 55:59–67. https://doi.org/10.3109/0284186X.2015.1027411

Article  PubMed  Google Scholar 

Padhani AR, Lecouvet FE, Tunariu N et al (2017) METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 71:81–92. https://doi.org/10.1016/j.eururo.2016.05.033

Article  PubMed  PubMed Central  Google Scholar 

Roach PJ, Francis R, Emmett L et al (2018) The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. J Nucl Med 59:82–88. https://doi.org/10.2967/jnumed.117.197160

Article  CAS  PubMed  Google Scholar 

Afshar-Oromieh A, Malcher A, Eder M et al (2013) PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40:486–495. https://doi.org/10.1007/s00259-012-2298-2

Article  CAS  PubMed  Google Scholar 

Eiber M, Maurer T, Souvatzoglou M et al (2015) Evaluation of hybrid ⁶⁸Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56:668–674. https://doi.org/10.2967/jnumed.115.154153

Article  PubMed  Google Scholar 

Cornford P, Van Den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 Update: treatment of relapsing and metastatic prostate cancer. Eur Urol 79:263–282. https://doi.org/10.1016/j.eururo.2020.09.046

Article  CAS  PubMed  Google Scholar 

Seifert R, Telli T, Opitz M et al (2023) Unspecific 18F-PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone scanning, and MRI triple validation in patients with biochemical recurrence of prostate cancer. J Nucl Med 64:738–743. https://doi.org/10.2967/jnumed.118.215434

Article  CAS  PubMed  Google Scholar 

Alberts IL, Seide SE, Mingels C et al (2021) Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging 48:2978–2989. https://doi.org/10.1007/s00259-021-05210-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Otani T, Saga T, Ishimori T et al (2022) Detection efficacy of PET/CT with 18F-FSU-880 in patients with suspected recurrent prostate cancer: a prospective single-center study. Ann Nucl Med 36:302–309. https://doi.org/10.1007/s12149-021-01704-6

Article  CAS  PubMed  Google Scholar 

Harada N, Kimura H, Onoe S et al (2016) Synthesis and biologic evaluation of novel 18F-labeled probes targeting prostate-specific membrane antigen for PET of prostate cancer. J Nucl Med 57:1978–1984. https://doi.org/10.2967/jnumed.116.175810

Article  CAS  PubMed  Google Scholar 

Aizawa R, Otani T, Ogata T et al (2024) Spatial pattern of intraprostatic recurrence after definitive external-beam radiation therapy for prostate cancer: implications for focal boost to intraprostatic dominant lesion. Adv Radiat Oncol 9:101489. https://doi.org/10.1016/j.adro.2024.101489

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malaspina S, Anttinen M, Taimen P et al (2021) Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. Eur J Nucl Med Mol Imaging 48:2951–2959. https://doi.org/10.1007/s00259-021-05296-1

Article  PubMed  PubMed Central  Google Scholar 

Kroenke M, Wurzer A, Schwamborn K et al (2020) Histologically confirmed diagnostic efficacy of 18F-rhPSMA-7 PET for N-staging of patients with primary high-risk prostate cancer. J Nucl Med 61:710–715. https://doi.org/10.2967/jnumed.119.234906

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anttinen M, Ettala O, Malaspina S et al (2021) A prospective comparison of 18F-prostate-specific membrane antigen-1007 positron emission tomography computed tomography, whole-body 1.5 T magnetic resonance imaging with diffusion-weighted imaging, and single-photon emission computed tomography/computed tomography with traditional imaging in primary distant metastasis staging of prostate cancer (PROSTAGE). Eur Urol Oncol 4:635–644. https://doi.org/10.1016/j.euo.2020.06.012

Article  PubMed  Google Scholar 

Sawicki LM, Kirchner J, Buddensieck C et al (2019) Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 46:1542–1550. https://doi.org/10.1007/s00259-019-04308-5

Article  CAS  PubMed  Google Scholar 

Afshar-Oromieh A, Sattler LP, Mier W et al (2017) The clinical impact of additional late PET/CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J Nucl Med 58:750–755. https://doi.org/10.2967/jnumed.116.183483

Article  CAS  PubMed  Google Scholar 

Aizawa R, Ogata T, Goto T et al (2025) Clinical outcomes of metastasis-directed therapy for oligo-metastatic prostate cancer diagnosed using PSMA-PET/CT or whole-body MRI. Anticancer Res 45:2515–2525

Article  PubMed  Google Scholar 

Eissa A, Elsherbiny A, Coelho RF et al (2018) The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: A systematic review of the literature. Minerva Urol Nefrol 70:462–478

Article  PubMed  Google Scholar 

Dyrberg E, Hendel HW, Huynh THV et al (2019) 68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study. Eur Radiol 29:1221–1230. https://doi.org/10.1007/s00330-018-5682-x

Article  PubMed